Pharmafile Logo
Pharmafocus logo
Advanced Search

treatment-resistant depression

Showing 2 posts of 2 posts found.

J&J seeks FDA approval of Spravato as monotherapy for treatment-resistant depression

July 24, 2024
Medical Communications J&J, Johnson & Johnson, Neurology, Spravato, treatment-resistant depression

Johnson & Johnson (J&J) has announced that it has submitted a supplemental New Drug Application (sNDA) to the US Food …

News
spravato

Janssen’s argues for the cost-effectiveness of Spravato in treatment-resistant depression

May 23, 2019
Sales and Marketing FDA, Janssen, depression, major depressive disorder, pharma, treatment-resistant depression

Janssen has unveiled a new cost-effectiveness analysis for its recently FDA-approved nasal spray Spravato (esketamine) in the treatment of treatment-resistant …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025